Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

1. Hepatitis B Virus Infection in Pregnant Women: Screening

Hepatitis B Virus Infection in Pregnant Women: Screening Final Recommendation Statement: Hepatitis B Virus Infection in Pregnant Women: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Hepatitis B Virus Infection in Pregnant Women: Screening Recommendations made by the USPSTF are independent (...) of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Recommendation Summary Population Recommendation Grade Pregnant women The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . Table

2019 U.S. Preventive Services Task Force

2. Pancreatic Cancer: Screening

Pancreatic Cancer: Screening Final Recommendation Statement: Pancreatic Cancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Pancreatic Cancer: Screening Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency (...) for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Adults The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . Table of Contents Preface The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients

2019 U.S. Preventive Services Task Force

3. Screening, Diagnosis, and Management of Placenta Accreta Spectrum Disorders

Screening, Diagnosis, and Management of Placenta Accreta Spectrum Disorders No. 383-Screening, Diagnosis, and Management of Placenta Accreta Spectrum Disorders - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 41, Issue 7, Pages 1035–1049 No. 383-Screening, Diagnosis, and Management of Placenta Accreta Spectrum Disorders x Sebastian R. Hobson , MD MPH PhD Toronto, ON x John C. Kingdom , MD Toronto, ON x Ally Murji , MD (...) accreta spectrum (PAS) disorders are a potentially life-threatening complication of pregnancy that demand coordinated interdisciplinary care to achieve safer outcomes. The rising incidence of this disease is due to a growing number of uterine surgical procedures, including the rising incidence of pregnancy following Caesarean section. Objective To provide current evidence-based guidelines on the optimal methods used to effectively screen, diagnose, and manage PAS disorders. Methods Members

2019 Society of Obstetricians and Gynaecologists of Canada

4. NHS population screening: inequalities strategy

NHS population screening: inequalities strategy NHS population screening: inequalities strategy - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance NHS population screening: inequalities strategy Guidance to support the health system to reduce inequalities in screening. Published 16 July 2019 From: Documents Ref: PHE publications gateway number GW-489 If you use assistive technology (such as a screen reader (...) ) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details The PHE Screening inequalities strategy is aimed at supporting local screening services, commissioners and others involved in the provision of screening to address inequalities. Published 16 July 2019 Related content Collection Explore the topic , , , , , , and Is this page useful? Thank you for your feedback Help us

2019 Public Health England

5. Newborn hearing screening programme (NHSP) operational guidance

Newborn hearing screening programme (NHSP) operational guidance Newborn hearing screening programme (NHSP) operational guidance - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Newborn hearing screening programme (NHSP) operational guidance This guidance supports healthcare professionals and stakeholders delivering and managing newborn hearing screening programmes in England. Published 1 November 2016 (...) Last updated 16 July 2019 — From: Documents HTML HTML HTML HTML HTML HTML HTML HTML HTML HTML HTML https://www.gov.uk/government/publications/newborn-hearing-screening-equipment-log-sheets If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. MS Word Document , 23.9KB This file may not be suitable for users

2019 Public Health England

6. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding - ACOG Menu ▼ Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding Page Navigation ▼ Number 785 Committee on Adolescent Health Care This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care (...) in collaboration with committee members Oluyemisi Adeyemi-Fowode, MD and Judith Simms-Cendan, MD. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding ABSTRACT : Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they should work in coordination with a hematologist for laboratory

2019 American College of Obstetricians and Gynecologists

7. Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine)

Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine) Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine) - INAHTA Brief

2019 Haute Autorite de sante

8. What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it?

What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it? Chiefs’ Inquiry Corner August 5th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner August 5th, 2019 August 5, 2019 2 min read Patients with chronic liver disease are nearly three times more likely to develop osteoporosis than matched controls. In contrast to patients with post-menopausal osteoporosis, in whom increased osteoclast activity depletes bone density, the mechanism (...) in patients with liver disease is thought to be driven by decreased osteoblast activity. Patients with liver disease see decreases in osteoblastogenesis stimulating factors such as IGF-1 and vitamin K and increases in serum bilirubin, which directly inhibits osteoblastogenesis. It is recommended to screen the following female and male patients for hepatic osteopenia: All patients with cirrhosis All patients with chronic cholestasis (bilirubin >3mg/dL for 6 months) All potential liver transplant candidates

2019 Clinical Correlations

9. Choosing Wisely Canada recommendation - Don’t routinely do screening mammography for average risk women aged 40 – 49. Individual assessment of each woman’s preferences and risk should guide the discussion and decision regarding mammography screening in th

Choosing Wisely Canada recommendation - Don’t routinely do screening mammography for average risk women aged 40 – 49. Individual assessment of each woman’s preferences and risk should guide the discussion and decision regarding mammography screening in th Don’t do imaging for lower-back pain unless red flags are present. Red flags include, but are not limited to, severe or progressive neurological deficits or when serious underlying conditions such as osteomyelitis are suspected. Imaging (...) all cases are viral. Though cases of bacterial sinusitis can benefit from antibiotics, evidence of such cases does not typically surface until after at least seven days of illness. Not only are antibiotics rarely indicated for upper respiratory illnesses, but some patients experience adverse effects from such medications. Don’t order screening chest X-rays and ECGs for asymptomatic or low risk outpatients. There is little evidence that detection of coronary artery stenosis in asymptomatic patients

2019 CPG Infobase

10. Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging

Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging Federal legislation proposes requiring that screening mammography reports to practitioners and women incorporate breast density information and that women with dense breasts discuss supplemental imaging with their practitioner given their increased risk of interval breast cancer. Instead of discussing supplemental imaging with all women with dense breasts, it may (...) be more efficient to identify women at high risk of advanced breast cancer who may benefit most from supplemental imaging.To identify women at high risk of advanced breast cancer to target woman-practitioner discussions about the need for supplemental imaging.This prospective cohort study assessed 638 856 women aged 40 to 74 years who had 1 693 163 screening digital mammograms taken at Breast Cancer Surveillance Consortium (BCSC) imaging facilities from January 3, 2005, to December 31, 2014. Data

2019 EvidenceUpdates

11. Breast screening: professional guidance

Breast screening: professional guidance Breast screening: professional guidance - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Collection Breast screening: professional guidance Standards and guidance for health professionals, managers and commissioners working in the NHS breast screening programme. Published 1 June 2015 Last updated 21 June 2019 — From: Contents Breast screening: commissioning and testing of X (...) -ray systems is published by Consolidated programme standards 15 August 2017 Guidance Programme guidelines Programme standards and guidance for breast pathology can be found on the 25 February 2019 Guidance 1 March 2009 Guidance 15 November 2016 Guidance 1 March 2011 Guidance 11 December 2017 Guidance 8 August 2017 Guidance 9 August 2017 Guidance 1 November 2018 Guidance 28 January 2019 Guidance Good practice in breast screening 31 August 2016 Guidance 1 July 2005 Guidance 1 July 2008 Guidance 9

2019 Public Health England

12. Breast screening: higher risk women surveillance protocols

Breast screening: higher risk women surveillance protocols Breast screening: higher risk women surveillance protocols - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Breast screening: higher risk women surveillance protocols The NHS breast surveillance protocols for women at higher risk of developing breast cancer. Published 1 June 2013 Last updated 8 July 2019 — From: Documents If you use assistive (...) technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. format This file may not be suitable for users of assistive technology. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive

2019 Public Health England

13. Breast screening: IMS Giotto Class digital mammography system in 2D mode

Breast screening: IMS Giotto Class digital mammography system in 2D mode Breast screening: IMS Giotto Class digital mammography system in 2D mode - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Breast screening: IMS Giotto Class digital mammography system in 2D mode Technical evaluation of the IMS Giotto Class digital mammography system in 2D mode, used in the NHS breast screening programme. Published 8 (...) July 2019 From: Documents Ref: PHE publications gateway number GW-524 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details The report is one of a series of technical reports evaluating commercially available mammography systems on behalf of the NHS breast screening programme. The report will help breast

2019 Public Health England

14. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial

Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial Digital breast tomosynthesis is an advancement of mammography, and has the potential to overcome limitations of standard digital mammography. This study aimed to compare first-generation digital breast tomo-synthesis including two-dimensional (2D) synthetic mammograms versus digital mammography in a population-based screening (...) programme.BreastScreen Norway offers all women aged 50-69 years two-view (craniocaudal and mediolateral oblique) mammographic screening every 2 years and does independent double reading with consensus. We asked all 32 976 women who attended the programme in Bergen in 2016-17, to participate in this randomised, controlled trial with a parallel group design. A study-specific software was developed to allocate women to either digital breast tomosynthesis or digital mammography using a 1:1 simple randomisation method

2019 EvidenceUpdates

15. Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Untreated HIV infection can result in significant morbidity, mortality, and HIV transmission. A 2012 review for the US Preventive Services Task Force (USPSTF) found antiretroviral therapy (ART) associated with improved clinical outcomes and decreased transmission risk in persons with CD4 cell counts less than 500/mm3.To update (...) the 2012 review on HIV screening to inform the USPSTF.Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from 2012 to June 2018, with surveillance through January 2019.Nonpregnant individuals 12 years and older; randomized clinical trials (RCTs) and controlled observational studies of screening vs no screening, alternative screening strategies, earlier vs later initiation of ART, and long-term harms of ART.One investigator abstracted data

2019 JAMA

16. Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Prenatal screening for HIV can inform use of interventions to reduce the risk of mother-to-child transmission. The US Preventive Services Task Force (USPSTF) previously found strong evidence that prenatal HIV screening reduced risk of mother-to-child transmission. The previous evidence review was conducted in 2012.To update the 2012 review on prenatal HIV (...) screening to inform the USPSTF.Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from 2012 to June 2018, with surveillance through January 2019.Pregnant persons 13 years and older; randomized clinical trials and cohort studies of screening vs no screening; risk of mother-to-child transmission or maternal or infant harms associated with antiretroviral therapy (ART) during pregnancy; screening yield at different intervals or in different risk

2019 JAMA

17. Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (PubMed)

Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Prostate cancer is the third most common cancer type in the United States overall, accounting for 9.5% of new cancer cases and 5% of cancer deaths. The goal of prostate-specific antigen (PSA)-based screening is to identify early-stage disease that can be treated successfully. The U.S. Preventive Services Task Force (USPSTF) reviewed evidence (...) on the benefits and harms of PSA-based screening and treatment of screen-detected prostate cancer. It found that PSA-based screening in men aged 55 to 69 years prevents approximately 1.3 deaths from prostate cancer over 13 years per 1000 men screened and 3 cases of metastatic cancer per 1000 men screened, with no reduction in all-cause mortality. No benefit was found for PSA-based screening in men aged 70 years and older. On the basis of its review, the USPSTF concluded that the decision for men aged 55 to 69

2019 Annals of Internal Medicine

18. Sickle cell and thalassaemia screening: newborn outcomes system

Sickle cell and thalassaemia screening: newborn outcomes system SCT newborn outcomes system: overview - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance SCT newborn outcomes system: overview Published 19 March 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write (...) to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/sickle-cell-and-thalassaemia-screening-newborn-outcomes-system/sct-newborn-outcomes-system-overview System overview The sickle cell and thalassaemia ( . team in Public Health England ( ( Is this page useful? Thank you

2019 Public Health England

19. Abdominal aortic aneurysm screening: ultrasound equipment guidelines

Abdominal aortic aneurysm screening: ultrasound equipment guidelines Abdominal aortic aneurysm screening: ultrasound equipment quality assurance guidelines - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Abdominal aortic aneurysm screening: ultrasound equipment quality assurance guidelines Updated 22 March 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open (...) Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/abdominal-aortic-aneurysm-screening-ultrasound-equipment-guidance/abdominal-aortic-aneurysm-screening-ultrasound

2019 Public Health England

20. Child vision screening

Child vision screening Service specification - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Service specification Updated 24 April 2019 Contents © Crown copyright 2019 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email (...) : . Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.gov.uk/government/publications/child-vision-screening/service-specification 1. Purpose 1.1 Purpose of the specification This service specification for the child vision screening programme outlines the service and quality expected by the commissioning body, currently the local authority, for the population for whom

2019 Public Health England